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Introduction

Conclusion

Informed consent involves understanding the risks and benefits of
trial enrollment. This is challenging in the phase I setting since true
quantitative information is never known. We therefore performed
an analysis of published radiation oncology (RO) phase I trials
emphasizing patient outcomes. To our knowledge, no such systemic
analysis has previously been published.

Approximately 1500 patients are enrolled per year in radiation
oncology phase I trials, the majority in the USA. Although the risk
of death is low (<1%), the risk of major toxicity is significant (>40%).
These figures have to be considered in the context of expected
benefit/toxicity of standard of care RO treatment. Although we were
able to quantify risk, we were unable to quantify benefit. Although
preliminary, this data sheds light on the risks of patient participation
in phase I RO trials.

Methods
All phase I and I/II RO clinical trials published in the years 2001,
2005 and 2009 were identified via a PubMed search. All trials utilized
radiation therapy, and many also included cytotoxic and/or biologic
agents. Articles only published in abstract form were excluded, as
were strict phase II trials, non-English studies, and non-cancer
pathologies. Variables extracted from the full-text of manuscripts
included demographics, treatment site, trial design, toxicity, ethical
and legal considerations, and response rate. In the event of multiple
adverse events in a single subject, these were calculated as per-study,
not per-subject.

Results
A total of 119 trials were identified, 17 trials were excluded since
the manuscript was unobtainable, leaving 102 trials for review (2001,
27; 2005, 45; and 2009, 30). Of these trials, 59% were performed
in the USA and 66% were multi-institutional. Sixty-eight percent
(68%) of trials were phase 1 and 32% were phase I/II trials. The
most frequent treatment sites were lung 22%, brain 12%, rectal
11%, and head-and-neck 11%. Seventy-one trials involved doseescalating a chemotherapeutic or biologic agent, 21 trials doseescalated radiation alone, 2 trials escalated both radiation and/or a
chemotherapeutic agent, and 8 trials involved no dose-escalation. All
but 18 trials used a traditional / modified Fibonacci design. A total
of 4553 subjects were enrolled; 65% were male, with a mean age of
62. Median or mean follow-up was 25.2 months. There were a total
of 39 treatment related deaths, and 1881 major toxicities (defined as
grade 3 or worse excluding death according to CTCAE criteria or
equivalent) corresponding to an average risk of 0.1% and 41% per
patient, respectively. The reporting of benefit was inconsistent and
highly variable preventing meaningful analysis.
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